Meaningful Improvement in General Health Outcomes with Guselkumab Treatment for Psoriatic Arthritis: Patient-Reported Outcomes Measurement Information System-29 Results from a Phase 3 Study

OBJECTIVE: The Phase 3 DISCOVER-1 study of guselkumab is the first randomized controlled trial to use Patient-Reported Outcomes Measurement Information System (PROMIS) measures to assess the effects of treatment on general health outcomes in patients with psoriatic arthritis (PsA). METHODS: Patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Orbai, Ana-Maria, Coates, Laura C., Deodhar, Atul, Helliwell, Philip S., Ritchlin, Christopher T., Leibowitz, Evan, Kollmeier, Alexa P., Hsia, Elizabeth C., Xu, Xie L., Sheng, Shihong, Jiang, Yusang, Liu, Yan, Han, Chenglong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584870/
https://www.ncbi.nlm.nih.gov/pubmed/35768650
http://dx.doi.org/10.1007/s40271-022-00588-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584870/
https://www.ncbi.nlm.nih.gov/pubmed/35768650
http://dx.doi.org/10.1007/s40271-022-00588-6

Ejemplares similares